Saturday, March 15, 2025

Creating liberating content

Oracle Corp’s (NYSE: ORCL)...

Oracle Corp (NYSE: ORCL) falls down to its knees, share dropped over 12.15%...

RTX Corp (NYSE: RTX)...

RTX Corp (NYSE: RTX) experienced a notable decline of -7.22%, amounting to $6.03...

GameStop Corp. (NYSE:GME) Quarter...

GameStop Corp. (NYSE: GME) to announce its second quarter fiscal 2023 results after...

Advanced Micro Devices (NASDAQ:AMD)...

Shares of Advanced Micro Devices (NASDAQ:AMD) drops 0.38% in afterhours in last trading...
HomeTagsIntercept Pharmaceuticals Inc. (NASDAQ:ICPT)

Tag: Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)

Intercept Pharmaceuticals, Inc.’s (NASDAQ:ICPT) OCA...

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) disclosed that REVERSE,...

Intercept Pharmaceuticals, Inc.’s (NASDAQ:ICPT) OCA Study Unable to Meet its Primary Endpoint

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) disclosed that REVERSE, a Phase 3 research investigating the safety and effectiveness of OCA in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), did not reach its main goal of a 1-stage histological improvement in fibrosis with no deterioration of NASH after up to 18 months of medication. In this cirrhotic patient cohort, no new safety signals for OCA were detected. Intercept Pharmaceuticals, Inc. (ICPT) inches up to trade at $13.6 with the average traded volume of 1.14 million shares. The firm's shares performance for...

Intercept Pharmaceuticals, Inc.’s...

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) disclosed that REVERSE, a Phase 3 research investigating the safety and effectiveness of OCA in patients with compensated cirrhosis due...
spot_img

Create a website from scratch

With Newspaper Theme you can drag and drop elements onto a page and customize them to perfection. Try it out today and create the perfect site to express yourself!